Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab
The Journal of Immunology · 2025
DOI: 10.1093/jimmun/vkaf182 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Rui Mu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, Unite…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antibodies, Monoclonal, Humanized, Piperidines, Adenine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Heart, Lung and Blood Institute, Merck Sharp & Dohme LLC, Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC.
Abstract (Originalsprache)
Immune checkpoint blockade has been shown to restore anti-tumor T-cell function and elicit durable responses in select solid and hematopoietic malignancies. However, single-agent anti-programmed death 1 (PD-1) antibodies proved less efficacious in patients with chronic lymphocytic leukemia (CLL). In patients with high-risk or relapsed/refractory CLL, we conducted a phase 2 study testing the combination of lead-in ibrutinib and up to 2 cycles of fludarabine, followed by continuous therapy with ibrutinib and 17 cycles of pembrolizumab administered every 3 weeks. A total of 15 patients were enrolled. In 10 patients evaluable for response, we observed 1 complete response and 9 partial responses. There was no discernible benefit of the combination beyond what is expected from ibrutinib monotherapy. However, 3 weeks after the first dose of pembrolizumab, we detected CD8 T-cell proliferation in a subset of patients, whom we called “immune responders.” In the responders, CD27-expressing CD8 T cells were relatively increased over immune nonresponders. Paired single-cell RNA and TCR sequencing revealed clonal expansion of activated GZMK+ CD8 effector memory and terminally differentiated effector cells. After 6 months of pembrolizumab treatment, the proportion of activated and proliferating CD8 T cells returned to baseline levels. Similarly, most novel clonotypes identified after 1 cycle of pembrolizumab decreased in frequency on long-term treatment. In summary, pembrolizumab did not improve the clinical response over ibrutinib monotherapy but transiently activated distinct clonotypes of CD8 T cells in a subset of CLL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States.
- Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
- Flow Cytometry Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States.
Förderung
- National Heart, Lung and Blood Institute
- Merck Sharp & Dohme LLC
- Investigator-Initiated Studies Program of Merck Sharp & Dohme LLC
Zitieren
APA
Mu, R., Hornick, K. M., Redekar, N., Chen, J., Nierman, P., Soto, S., Herur, R., Sun, C., Saleh, L., Mhibik, M., Keyvanfar, K., Ahn, I. E., & Wiestner, A. (2025). Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf182
Vancouver
Mu R, Hornick KM, Redekar N, Chen J, Nierman P, Soto S, et al. Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf182
BibTeX
@article{Mu2025,
author = {Mu, Rui and Hornick, Katherine M and Redekar, Neelam and Chen, Jonathan and Nierman, Pia and Soto, Susan and Herur, Rohan and Sun, Clare and Saleh, Layla and Mhibik, Maissa and Keyvanfar, Keyvan and Ahn, Inhye E and Wiestner, Adrian},
title = {Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab},
journal = {The Journal of Immunology},
year = {2025},
doi = {10.1093/jimmun/vkaf182}
}
EUVIMED